← Leaderboards
Hong Yu Li
Synactix Pharmaceuticals, Inc.
$392,875
Attributed
$885,742
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $585.8K · FY2015–18$1M$750K$500K$250K$0
'15
'16
'17
'18
Funding mix
By agency
NIH$885,742 · 3
By mechanism
R41$885,742 · 3
Top collaborators
- Brendan Andrew Frett2 shared
- Monica L Guzman1 shared
- Neil P Shah1 shared
Most similar at Synactix Pharmaceuticals, Inc.
Same institution · by research overlap
- Brendan Andrew Frett$1,221,643
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsPharmacodynamicsInhibitor/AntagonistInhibitory Concentration 50MutationPharmaceutical PreparationsGrowthHourAqueousCancer PatientMedicineMonitorCellsOrganic AcidEffective TherapyGenerationsBiopsyDoseDrug DevelopmentDrug FormulationsDrug KineticsDrug PackagingCanis FamiliarisPlasma
Grant awards (3)
Preclinical studies of Selective and Orally Bioavailable Aurora B Inhibitors for the Treatment of AML$299,975
R41 · FY2018 · CA · contact PI
Pre-IND Study of Pz-1, a dual pan-RET/VEGFR2 inhibitor for the Treatment of RET-driven Disease$299,975
R41 · FY2015 · CA · contact PI
Pre-IND study of PMT-254, a pan-FLT3 inhibitor for the treatment of FLT3 driven cancers.$285,792
R41 · FY2015 · CA